How this investigational therapy could help:

Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that helps drive airway inflammation and asthma exacerbations. GB-0895 is an investigational antibody that binds and neutralizes TSLP to help reduce downstream inflammatory signaling in severe asthma. It is engineered for an extended half-life and is being studied for twice-yearly subcutaneous dosing, which may offer administration flexibility and convenience if proven safe and effective. GB-0895 is currently being evaluated in Phase 3 clinical studies.

How this investigational therapy could help:

Thymic stromal lymphopoietin (TSLP) is an epithelial cytokine that contributes to airway inflammation and disease progression in COPD. GB-0895 is an investigational antibody designed to bind and neutralize TSLP, with the goal of reducing downstream inflammatory signaling in chronic airway disease. GB-0895 has been engineered for an extended half-life and is being evaluated in a Phase 1 clinical study in COPD to assess safety, pharmacokinetics, and pharmacodynamic activity.

How this investigational therapy could help:

GB-4362 is a monoclonal antibody designed to selectively bind free monomethyl auristatin E (MMAE). Free MMAE is associated with systemic toxicities when released from MMAE-based antibody-drug conjugates. GB-4362 is designed to reduce circulating free MMAE without interacting with intact ADCs.

How this investigational therapy could help:

GB-5267 is an IL-18 armored CAR T-cell therapy targeting MUC16, a cell-surface antigen highly expressed in ovarian cancer. It is designed to redirect autologous T cells to recognize and kill MUC16-expressing tumor cells. The therapy is engineered to enhance T-cell activation, proliferation, and persistence within the tumor microenvironment.